Pipeline Framework: Specialised – Icatibant and C1 Esterase products for the treatment of Hereditary Angioedema

A pipeline has been launched for Specialised – Icatibant and C1 Esterase products for the treatment of Hereditary Angioedema.The contract start Date is 01 January 2020. Approach to market date is 30 September 2019.Icatibant and C1 Esterase products for the treatment of Hereditary AngioedemaThis is a potential opportunity from the government, and the pipeline gives advance notice of an opportunity that might be offered by the public sector in the future – allowing potential suppliers to plan accordingly. When a public sector organisation publishes a pipeline notice, it does not necessarily mean that an opportunity will be offered in the future.For more information contact: Commercial Medicines Unit – NHS England, 2nd Floor, Rutland House, Runcorn WA7 2ES. Email: alison.greenwood3@nhs.net